Stocks to buy

The coronavirus pandemic disrupted many businesses and was a boon to others. One sector that’s been riding high is the pharmaceutical industry. That’s especially true for companies that have brought a Covid-19 vaccine to market. Vaccine developer Novavax (NASDAQ:NVAX) is a perfect example. NVAX stock rose from relative obscurity with a share price of just
0 Comments
Nvidia’s (NASDAQ:NVDA) core businesses have been firing on all cylinders, and its move into other profitable verticals has resulted in consistent top-line growth.  The company’s market value has grown at an incredible pace over the past decade. Yet, NVDA stock still has a ton of upside left with new catalysts that will amplify growth in
0 Comments
Biotech stocks are infamously one of the most volatile sectors in the stock market. Investors often venture into speculative companies with no proven pipelines. Emerging firms with a pipeline of drugs and products still in the clinical phase post little to no revenue. They raise cash by tapping capital markets to pay for research and
0 Comments
Editor’s Note: This article is part of Joanna’s Top Trades — a weekly feature dedicated toward making you money within a specific space. Joanna’s pick for this week is Zoom (NASDAQ:ZM) as the top stock to trade this week. We all know video-calling software maker Zoom (NASDAQ:ZM). The pandemic high-flier capitalized on a stay-at-home workforce, growing
0 Comments
Commodity prices keep rising amid various supply chain disruptions. That’s causing panic buying of raw materials. As a result, many commodity stocks have reported strong numbers in their recent earnings reports, and banking analysts seem to think that inflationary prices will continue to drive earnings higher. I’d argue that there’s an added dynamic to many
0 Comments
The markets are far from efficient right now, with several undervalued stocks that boast historically-stable cash flows, scandal-free operations, and a robust profitability profile, relegated to the background. Most of the column inches and headlines are reserved for hyper-growth stocks and exciting recovery plays. Post-pandemic, the outlook for several exceptional stocks remains pessimistic because of
0 Comments